Syngene International's quarterly market cap
increased
from Sep. 2025 (₹250,209 Mil) to Dec. 2025 (₹261,541 Mil) but then
declined
from Dec. 2025 (₹261,541 Mil) to Mar. 2026 (₹156,651 Mil).
Syngene International's annual market cap
increased
from Mar. 2024 (₹281,562 Mil) to Mar. 2025 (₹291,471 Mil) but then
declined
from Mar. 2025 (₹291,471 Mil) to Mar. 2026 (₹156,651 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Syngene International's Enterprise Value for Today is ₹160,578 Mil.
Syngene International (NSE:SYNGENE) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:SYNGENE vs TMO, DHR, IDXX: Market Cap Comparison
For the Diagnostics & Research subindustry, Syngene International's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Syngene International Market Cap vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Syngene International's Market Cap distribution charts can be found below:
* The bar in red indicates where Syngene International's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Syngene International's Market Cap for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Syngene International (NSE:SYNGENE) has a Market Cap of ₹168,885 Mil as of Jul. 13, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Syngene International and its competitors. According to the industry distribution chart, Syngene International ranks #41 out of 217 companies in the Medical Diagnostics & Research industry, placing it in the top 18.9%.
Is Syngene International's Market Cap too high?
Syngene International's current Market Cap is ₹168,885 Mil. Based on the distribution chart, Syngene International ranks #41 out of 217 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Syngene International has a GF Score™ of 86/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Syngene International's Market Cap compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Syngene International ranks #41 out of 217 companies for Market Cap. This places Syngene International in the top 19% of its industry — outperforming the majority of peers. The industry median Market Cap is 61.53. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Diagnostics & Research company?
The median Market Cap among Medical Diagnostics & Research companies is 61.53, based on 217 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Syngene International and its competitors. For the Medical Diagnostics & Research industry, the median Market Cap is 61.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Syngene International's current Market Cap is ₹168,885 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syngene International stock overvalued right now?
Based on GuruFocus' analysis, Syngene International (NSE:SYNGENE) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹768.98, compared to a current price of ₹420.35 — trading 45.3% below its estimated fair value. The current Market Cap is ₹168,885 Mil. Syngene International's overall GF Score™ is 86/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Syngene International (NSE:SYNGENE), the current Market Cap is ₹168,885 Mil as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Syngene International (NSE:SYNGENE) Overvalued in 2026?
Based on GuruFocus' analysis, Syngene International stock appears to be undervalued.
The current stock price of ₹420.35 is trading 45.3% below its estimated GF Value™ of ₹768.98.
GuruFocus considers Syngene International to be Significantly Undervalued.
Key valuation signals for NSE:SYNGENE:
Market Cap: ₹168,885 Mil
GF Value™: ₹768.98 vs. price of ₹420.35 (45.3% below fair value)
No single metric tells the full story. See the NSE:SYNGENE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Syngene International Ltd is a contract research and manufacturing organization in India. It supports research and development programs, from lead generation to clinical and commercial supplies. The Company is engaged in a single operating segment of providing contract research and manufacturing services. The company operates in India, the United States of America and other countries, of which a majority of the revenue is derived from the USA. The company receives revenue by providing contract research and manufacturing services. It offers services such as Oligonucleotide synthesis, Bioinformatics, Clinical development services, polymer research, chemical development, safety assessment, discovery chemistry, discovery biology, and others.
86GF Score
Get the complete analysis for NSE:SYNGENE
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SYNGENE has been successfully added to your 
